Global Analysis Shows Significant Variability in Sarcoma Clinical Trial Availability High variability in sarcoma clinical trial funding, location, and phase was identified in a global analysis conducted over the past decade.

Global Analysis Shows Significant Variability in Sarcoma Clinical Trial Availability
@myesmo.bsky.social #ESMORareCancers25 #Sarcoma
www.onclive.com/view/global-...

Nirogacestat Provides Long-Term Benefits in Desmoid Tumors Nirogacestat sustained long-term efficacy with acceptable safety in patients with desmoid tumors treated in the phase 3 DeFi trial.

Nirogacestat Provides Long-Term Benefits in Desmoid Tumors @myesmo.bsky.social #ESMORareCancers25 #scmsm #oncology
www.onclive.com/view/nirogac...

Reduced Radiotherapy Margins Yield Outcomes Comparable With Standard Margins in HGG A randomized trial found no significant differences in recurrence or survival with smaller radiation margins vs standard RTOG protocols in patients with HGG.

Reduced Radiotherapy Margins Yield Outcomes Comparable With Standard Margins in HGG @myesmo.bsky.social #ESMORareCancers25 #btsm #oncology
www.onclive.com/view/reduced...

A pleasure contributing to #ESMORareCancers25 with a talk about #adrenocorticalcarcinoma. Well done Alessandra Mangone presenting our #ENSAT study on predictors of treatment response & Emanuela Esposito for poster on #PLK1 inhibitors 👏 👏 #MedSky #EndoSky @unibirmingham.bsky.social
ow.ly/yNk150Vm4hC

Delighted our team won best poster at #ESMORareCancers25 with work spearheaded by former PhD @LSJones4. Work coming out shortly in @SciReports #dmd #hnscc

Fascinating discussion about the role of mentorship in developing a career in rare tumors!
#ESMORareCancers25 @lizconnolly.bsky.social

Congrats to @amalsargsyan & @dmbranco.bsky.social for having abstracts selected for #oralpresentation at
#ESMORarecancers25!

Excellent work in helping community understand current issues w/ #sarcoma #clinicaltrials access & #impression of #realworldevidence for drug approvals.

#drugdevelopment

We are kicking off @myesmo.bsky.social #ESMORareCancers25 in Lugano 🇨🇭 this morning! Looking forward to 3 days of interactions with experts in #sarcomas and other #rarediseases from around the 🌎. #CUHKSarcoma #CTOSTweeTOS

👉 Watch Prof. Gietema, Dr. Trama, Dr. Valverde & Prof. Girard discuss how collaboration drives better outcomes for rare cancer patients. Submit your abstract for ESMO Sarcoma and Rare Cancers 2025 by 7 Jan & join the conversation! #ESMORareCancers25
🔗 ow.ly/bxph50Ua6zJ